Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …

ABSTRACT Introduction Various pharmacogenomic (PGx) variants differ widely in different
ethnicities. and clinical outcomes associated with these variants may also be substantially …

Pharmacogenomic (PGx) testing of cytochrome P450 (CYP) enzymes may improve the
efficacy and/or safety of some medications. This is facilitated by increased availability and …

In the past two decades, significant progress has been made in the development of
polygenic scores (PGSs). One specific application of PGSs is the development and potential …

There is considerable interindividual variability in the response to antiplatelet and
anticoagulant therapies, and this variation may be attributable to genetic variants. There has …

Background: Awareness about the importance of implementing DPYD pharmacogenetics in
clinical practice to prevent severe side effects related to the use of fluoropyrimidines has …

There is considerable inter-individual variability in the effectiveness and safety of
pharmaceutical interventions. This phenomenon can be attributed to a multitude of factors; …

Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide.
It is widely accepted that both concomitant medications (drug–drug interactions, DDIs) and …

Background: Despite evidence of clinical utility and the availability of prescription guidelines,
pharmacogenomics (PGx) is not broadly used in institutional settings in Canada. To inform …

Since the rebirth of pharmacogenomics (PGx) in the 1990s and 2000s, with new discoveries
of genetic variation underlying adverse drug response and new analytical technologies such …